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Chitinase 1 regulates pulmonary ﬁbrosis by modulating
TGF-β/SMAD7 pathway via TGFBRAP1 and FOXO3
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Roberto Cotez1, Emily Chen1, Yang Zhou1, Erica L Herzog3, Changwan Ryu2, Xueyan Peng2, Ivan O Rosas4, Sergio Poli4,
Carol Feghali Bostwick5, Augustine M Choi6, Jack A Elias1,7, Chun Geun Lee1
TGF-β1 is a critical mediator of tissue ﬁbrosis in health and disease
whose effects are augmented by chitinase 1 (CHIT1). However, the
mechanisms that CHIT1 uses to regulate TGF-β1–mediated ﬁbrotic
responses have not been deﬁned. Here, we demonstrate that CHIT1
enhances TGF-β1–stimulated ﬁbrotic cellular and tissue responses
and TGF-β1 signaling. Importantly, we also demonstrate that these
effects are mediated by the ability of CHIT1 to inhibit TGF-β1 in-
duction of its feedback inhibitor, SMAD7. CHIT1 also interacted with
TGF-β receptor associated protein 1 (TGFBRAP1) and forkhead box
O3 (FOXO3) with TGFBRAP1 playing a critical role in CHIT1 en-
hancement of TGF-β1 signaling and effector responses and FOXO3
playing a critical role in TGF-β1 induction of SMAD7. These pathways
were disease relevant because the levels of CHIT1 were increased
and inversely correlated with SMAD7 in tissues from patients with
idiopathic pulmonary ﬁbrosis or scleroderma-associated interstitial
lung disease. These studies demonstrate that CHIT1 regulates TGF-
β1/SMAD7 axis via TGFBRAP1 and FOXO3 and highlight the impor-
tance of these pathways in the pathogenesis of pulmonary ﬁbrosis.
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Introduction
TGF-β1 is a pleiotropic regulator of essential biologic responses
(Massague, 1998). Central to its biology are its well-documented
roles in wound healing and its importance as a regulator of in-
ﬂammation, and cell survival, differentiation, motility, proliferation,
and adhesion (Bowen et al, 2013). TGF-β1 dysregulation has been
implicated in the pathogenesis of a wide variety of diseases and is a
potent regulator of scarring in human diseases characterized by
ﬁbrogenesis (Bowen et al, 2013). In many of these disorders, the
overexpression of TGF-β1 has been documented. In other diseases,
such as scleroderma (SSc), exaggerated levels of TGF-β1 are not
seen, but TGF-β1 signatures are appreciated (Sargent et al, 2010). In
keeping with its multifaceted effector functions and complex roles
in health and disease, it is now clear that the production and
effector responses of TGF-β1 are under precise control (Bowen et al,
2013). The factors that regulate TGF-β1 effector response, however,
have not been adequately deﬁned.
The GH 18 gene family contains true chitinases that bind and
cleave chitin. Chitinase 1 (CHIT1, chitotriosidase) is the most readily
appreciated true chitinase in mammals and man. It can be found in
the circulation and tissues of normal controls and patients with
disorders characterized by inﬂammation and remodeling such as
Gaucher’s disease, sarcoidosis, chronic obstructive pulmonary
disease, and interstitial pulmonary ﬁbrosis (Cho et al, 2015).
However, its roles in these disorders are poorly understood be-
cause chitin (the only known substrate of chitinases) does not exist
in mammals. Previous studies from our laboratory demonstrated
that the levels of CHIT1 activity are increased in patients with SSc
with interstitial lung disease (SSc-ILD) where they correlate with
disease severity (Lee et al, 2012). In vivo and in vitro investigations
also demonstrated that CHIT1 interacted with TGF-β1 to augment
TGF-β1 receptor–induced SMAD and MAPK and AKT signaling (Lee
et al, 2012). These studies demonstrate that CHIT1 is a biomarker for
TGF-β1 in SSc-ILD where it augments TGF-β1 signaling (Lee et al,
2012). However, the mechanism(s) by which these ﬁbrogenic effects
of CHIT1 are mediated have not been adequately deﬁned.
The effects of TGF-β1 ligands are mediated by type 1 and type 2
receptors (Huang & Chen, 2012). They activate and phosphorylate
receptor-regulated SMAD proteins (SMAD2 and 3), which form a
heterometric complex with SMAD4. The complexes then translocate
to the nucleus where it regulates gene expression and activates
canonical and noncanonical signaling pathways (Miyazawa &
Miyazono, 2017). In keeping with the critical importance of the
regulation of TGF-β1 effector responses, TGF-β1 signaling is regu-
lated by a variety of inhibitory mechanisms (Miyazawa & Miyazono,
2017). Inhibitory SMADs, in particular SMAD7, are induced by TGF-β1
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and feedback to control TGF-β1 signaling responses (Yan et al, 2009;
Sureshbabu et al, 2016). In addition to TGF-β1, a variety of other
cytokines and microRNA regulate SMAD7. However, a relationship
between CHIT1 and SMAD7 has not been deﬁned.
To further understand the mechanisms that CHIT1 uses to
regulate TGF-β1 response, in vivo and in vitro approaches were
used to deﬁne the roles of CHIT1 and themechanisms that it uses in
pulmonary ﬁbrosis. These studies demonstrate that CHIT1 aug-
ments TGF-β1–stimulated ﬁbroblast proliferation, myoﬁbroblast
differentiation, and canonical and noncanonical signaling. They
also demonstrate that these responses are mediated by the ability
of CHIT1 to inhibit SMAD7 via interaction with TGF-β receptor–
associated protein 1 (TGFBRAP1) and FOXO3. Last, they highlight the
disease relevance of these ﬁndings by demonstrating the increased
levels of CHIT1 and decrease in SMAD7 in lung tissues from patients
with idiopathic pulmonary ﬁbrosis (IPF) or SSc-ILD.
Results
CHIT1 enhances TGF-β1–stimulated ﬁbroblast responses in vitro
To determine if CHIT1 has signiﬁcant effects on the TGF-β1–
stimulated cellular responses that could contribute to ﬁbrosis, we
stimulated normal human lung ﬁbroblasts (NHLFs) with recombi-
nant (r) CHIT1 alone, or in combination with TGF-β1. CHIT1 by itself
did not stimulate ﬁbroblast proliferation, but it did enhance TGF-
β1–stimulated ﬁbroblast proliferation as measured by WST-1 assay
(Fig 1A). Similarly, CHIT1 did not alter ﬁbroblast differentiation into
myoﬁbroblasts as assessed by α-smooth muscle actin (α-SMA)
accumulation, but it augmented the ability of TGF-β1 to enhance
α-SMA accumulation (Fig 1B). This suggests that CHIT1 enhances
TGF-β1–stimulatedmyoﬁbroblast transformation. In accord with these
ﬁndings, TGF-β1 stimulated the expression of vimentin, paxicillin,
ﬁbronectin, and other extracellular matrix (ECM) genes such as
elastin and collagen, and these effects were signiﬁcantly enhanced
by CHIT1 (Fig 1C). Collectively, these results indicate that CHIT1
enhances TGF-β1–stimulated ﬁbroblast proliferation, myoﬁbroblast
transformation, and ECM expression.
CHIT1 enhances and plays a critical role in TGF-β1–stimulated
ﬁbrotic responses in vivo
Studies were next undertaken to determine if CHIT1 inﬂuenced TGF-
β1–induced ﬁbrotic responses in vivo. In these experiments, we ﬁrst
compared the regulation of ECM proteins in transgenic mice in
which CHIT1 and TGF-β1 were overexpressed in the lungs, indi-
vidually or in combination. We also compared the effects of
Figure 1. CHIT1 enhances TGF-β1-stimulated
ﬁbroblast responses in vitro.
NHLF were stimulated with recombinant (r) TGF-β1
(rTGF-β, 10 ng/ml) and rCHIT1 (250 ng/ml) for 24 h then
the effect of rTGF-β and rCHIT1 was evaluated. (A)
Fibroblast cell proliferation assay by WST-1. (B)
Immunohistochemistry (IHC) using anti–α-smooth
muscle actin; Con, controls with no rTGF-β or rCHIT1
stimulation. (C) Expression of markers of myoﬁbroblasts
and extracellular protein accumulation assessed by
real-time quantitative reverse transcription PCR (qRT-
PCR). β-actin was used as an internal control. The values
in panels A and C represent mean ± SEM of triplicated
evaluations in a minimum of two separate experiments.
Panel B is a representative IHC in a minimum of three
separate experiments. *P < 0.05, **P < 0.01, t test. Bars in
panel B, 50 μM.
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transgenic TGF-β1 in mice with wild-type or null mutant CHIT1
alleles. In accord with our in vitro ﬁndings cited above, although
transgenic or null mutation of CHIT1 alone did not stimulate or
suppress, transgenic TGF-β1 was a signiﬁcant stimulator and CHIT1
and TGF-β1 interacted to further stimulate the expression of ECM
proteins, including ﬁbronectin, elastin, and type 1 collagen (Fig 2A).
Importantly, the ability of TGF-β1 to stimulate ECM proteins was at
least partially dependent on CHIT1 because the stimulatory effects
of transgenic TGF-β1 were signiﬁcantly decreased in mice with null
CHIT1 loci (Fig 2B and C). When viewed in combination, these studies
demonstrate that CHIT1 is both necessary and sufﬁcient for optimal
TGF-β1–stimulated ﬁbrotic ECM tissue response in the lungs.
CHIT1 augments TGF-β signaling in the lung
Studies were next undertaken to deﬁne the role(s) of CHIT1 in TGF-β
signaling. In these experiments, we compared the activation of
canonical TGF-β1 signaling pathways in the lungs from transgenic
mice in which CHIT1 and TGF-β1 were targeted to the lung, alone
and in combination. This approach was undertaken because pre-
vious studies from our laboratory highlighted the exaggerated ﬁ-
brotic responses in the lungs from mice in which CHIT1 and TGF-β1
were simultaneously expressed compared with mice in which each
was expressed individually (Lee et al, 2012). As can be seen in Fig 2D,
the present studies demonstrated that transgenic TGF-β1 increased
canonical Smad2/3, MAPK/Erk, and Akt activation compared with
wild-type control mice and activation of these signaling pathways
was further enhanced in the co-expression of TGF-β1 and Chit1.
These studies demonstrate that CHIT1 augments TGF-β1 signaling in
vivo.
CHIT1 inhibits the expression of inhibitory SMAD7
TGF-β1 is well known to induce SMAD7 which, in turn, feeds back to
control TGF-β1 signaling and effector responses (Zhao et al, 2000).
The studies described above demonstrate that CHIT1 augments
TGF-β1 signaling and ﬁbrotic responses. This led us to hypothesize
that the effects of CHIT1 might be mediated via alterations in the
ability of TGF-β1 to induce SMAD7. To test this hypothesis, we
compared the expression of Samd7 in in the lungs from transgenic
mice in which Chit1 and TGF-β1 were expressed, alone and in
combination. In these experiments, transgenic TGF-β1 was a potent
stimulator, and transgenic Chit1 did not signiﬁcantly alter the ex-
pression of Smad7 (Fig 2E). Importantly, when Chit1 and TGF-β1 were
simultaneously overexpressed, the ability of TGF-β1 to stimulate
Samd7 was markedly ameliorated (Fig 2E). These studies demon-
strate that CHIT1 inhibits the ability of TGF-β1 to induce inhibitory
SMAD7. In so doing, they support the concept that the synergistic
interactions of CHIT1 and TGF-β1 are mediated, at least in part, by
the ability of CHIT1 to inhibit the SMAD7-mediated feedback in-
hibition that normally controls TGF-β1 response.
CHIT1 interacts with TGFBRAP1 and FOXO3
Studies were next undertaken to further deﬁne the mechanisms
that CHIT1 uses to regulate TGF-β1 signaling and cell and tissue
responses. Because CHIT1 is a secreted protein that can be found in
both extracellular and intracellular compartments, we ﬁrst un-
dertook studies to deﬁne its potential binding partner(s). Potential
CHIT1-binding partners were ﬁrst deﬁned using yeast 2 hybrid (Y2H)
screening assays with a lung cDNA library. This approach identiﬁed
several CHIT1-binding proteins, including TGFBRAP1 and FOXO3
(Table S1). TGFBRAP1 has been reported to be a chaperone for SMAD
signaling (Wurthner et al, 2001) and FOXO3 is an transcription factor
for multiple genes that play critical roles in metabolism, cellular
stress response, tissue remodeling, and disease progression (Nho
& Hergert, 2014; Webb et al, 2016). In keeping with their potential
importance, the results of the Y2H assays were further evaluated
using co-immunoprecipitation (Co-IP) and co-localization assays.
The Co-IP and immunoblot evaluations of cells transfected with
CHIT1, TGFBRAP1, and FOXO3 demonstrated signiﬁcant molecular
interactions between CHIT1 and TGFBRAP1 or FOXO3 (Fig 3A). The
molecular interaction between CHIT1 and TGFBRAP1 or FOXO3 was
further supported by the co-localization immunohistochemical
evaluations on the NHLF after stimulation with recombinant TGF-β
(Fig 3B). We noted similar pattern of CHIT1 expression and co-
localization with TGFBRAP1 or FOXO3 in epithelial cells and mac-
rophages (data not shown). When viewed in combination, these
studies demonstrate that CHIT1 interacts with TGFBRAP1 and FOXO3.
TGFBRAP1 plays a critical role in CHIT1 augmentation of TGF-β1
signaling
To deﬁne the role(s) of TGFBRAP1 in CHIT1 regulation of TGF-β
signaling, gene-speciﬁc siRNA silencing was used. In these ex-
periments, NHLF cells were stimulated with rTGF-β1 (10 ng/ml) and
rCHIT1 (250 ng/ml), alone and in combination, for 1 h. Comparisons
were made of cells treated with TGFBRAP1 siRNA (which decreased
the levels of TGFBRAP1 protein expression by >75%, Fig 4A) or
scrambled controls. As noted above, the simultaneous treatment of
ﬁbroblasts with recombinant CHIT1 with TGF-β1 enhanced the
ability of TGF-β1 to activate SMAD2 and MAPK/ERK and AKT. Im-
portantly, these CHIT1-stimulated TGF-β1 responses were markedly
decreased in cells treated with TGFBRAP1 siRNA (Fig 4A). We also
noted modest decreases in TGFβR1 expression with TGFBRAP1 si-
lencing, suggesting that Chit1 regulates TGF-β receptor expression
via TGFBRAP1, at least in part. Luciferease-tagged SMAD2 promotor
assay further conﬁrmed that silencing of TGFBRAP1 ameliorate the
CHIT1-induced promoter activity of SMAD2 with TGF-β stimulation
(Fig 4B). Collectively, these studies indicate that TGFBRAP1 plays an
essential role in the ability of CHIT1 to augment canonical and
noncanonical TGF-β1 signaling and TGFβR expression.
TGF-β1 stimulates SMAD7 via FOXO3
The studies noted above demonstrate that CHIT1 interacts with
FOXO3, and we identiﬁed a FOXO3-binding site in the promoter
region of SMAD7. This led us to investigate whether FOXO3 plays a
role in TGF-β1 and or CHIT1’s regulation of SMAD7 expression. In
these experiments, NHLF cells were treated with TGF-β1 and rCHIT1,
alone or in combination, with and without siRNA silencing of FOXO3.
The siRNA that were used in these experiments decreased the
levels of FOXO3 by >70% (Fig S1). As noted above, TGF-β1 treatment
increased SMAD7 mRNA expression in a manner that was reduced
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Figure 2. CHIT1 enhances and plays a critical role in TGF-β1–stimulated signaling and ﬁbrotic responses in vivo.
6–8-wk-old WT (−), TGF-β Tg (+), Chit1 Tg (+), and Chit1 Tg/TGF-β Tg mice were subjected to the evaluation. These mice were euthanized after 14 d of transgene
induction of doxycycline containing drinking water (0.5 g/l). The expression levels of TGF-β1 and Chit1 in the bronchoalveolar lavage measured ELISA were about
1.8 ± 0.2 ng/ml and 13 ng ± 2.3/ml for TGF-β Tg and Chit1 Tg, respectively. (A, B) Evaluation on the ECM-associated gene expression and collagen accumulation in the lungs of
WT and TGF-β Tg mice with overexpression of Chit1 (Chit1 Tg) (A) or null mutation of Chit1 (Chit1−/−) (B) using real-time qRT-PCR or Sircol Collagen Assay. β-actin
was used as an internal control. (C) Representative Mallory’s trichrome staining of the lungs from TGF-β Tg mice with null mutation of Chit1 (Chit−/−). (D, E) Western blot
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by the simultaneous administration of CHIT1 (Fig 5A). In these
experiments, the silencing of FOXO3 reduced TGF-β1–stimulated
SMAD7 expression to the levels comparable with those seen in
control cells (Fig 5A). The role of FOXO3 in TGF-β1–stimulated SMAD7
expression was further validated using SMAD7 promoter-luciferase
assays. In these experiments, HEK293 cells were transfected with
SMAD7 promoter-luciferase constructs that contain a wild-type FOXO3
consensus sequence (ProSMAD7WT) (GTAAAC, located −802 bp up-
stream of SMAD7 translation initiation site) (Fig S2) and SMAD7 lu-
ciferase activity was evaluated after treatment with recombinant
TGF-β1 and CHIT1, alone or in combination. As shown in Fig 5B, TGF-
β1 stimulated SMAD7 luciferase activity in a manner that was op-
posed by co-administration of rCHIT1. As can also be seen in Fig 5B,
this stimulation was SMAD7-dependent because SMAD7 luciferase
activity was not induced by TGF-β1 in cells that had been trans-
fected with a mutant SMAD7 promoter construct (ProSMAD7,(Foxo)),
which did not contain a FOXO3 consensus sequence. When viewed
in combination, these studies demonstrate that the transcription
factor FOXO3 plays a critical role in TGF-β1 stimulation of SMAD7
expression.
CHIT1 reduces the levels of TGF-β–stimulated nuclear
FOXO3/pFOXO3
Our studies demonstrate that TGF-β1 stimulates SMAD7 via FOXO3,
whereas CHIT1 inhibits TGF-β1–stimulated SMAD7. This led us to
determine if the inhibitory effects of CHIT1 could be attributed to its
ability to regulate FOXO3. To address this issue, we evaluated the
expression of Foxo3 and pFoxo3 in whole-cell lysates and the
cellular nuclear and cytoplasmic fractions from the cells of lungs
from WT mice and mice in which TGF-β1 and or Chit1 were targeted
to the lungs. As shown in Fig 5C, transgenic TGF-β1 modestly in-
creased the levels of Foxo3 and pFoxo3 in the whole-lung lysates
and their nuclear and cytoplasmic fractions. Although transgenic
Chit1 did not signiﬁcantly alter the expression of Foxo3 and pFoxo3
by itself, it did increase the levels of TGF-β1–stimulated Foxo3 or
pFoxo3 in the whole-lung lysates (Fig 5C). This was mainly due to a
signiﬁcant increase in cytoplasmic Foxo3 and pFoxo3 with de-
creased nuclear fraction of these moieties (Fig 5C). These studies
demonstrate that CHIT1 regulates the ability of TGF-β1 to induce
the nuclear transcription factor FOXO3 and suggests that CHIT1
inhibits TGF-β1 induction of SMAD7 by decreasing nuclear FOXO3
accumulation.
The levels of CHIT1 expression are increased in IPF where they
correlate inversely with SMAD7
Studies were next undertaken to determine if our murine ﬁndings
are relevant to patients with IPF. Because CHIT1 augmented TGF-
β1–induced ﬁbrotic tissue responses by inhibiting SMAD7, we
characterized the expression of CHIT1 and SMAD7 in tissues and
cells from IPF patients and normal controls. As shown in Fig 6A, the
levels of mRNA encoding CHIT1 were signiﬁcantly higher in the
lungs from patients with IPF compared with normal controls. In
accord with our murine studies, there was an inverse correlation
between the levels of expression of SMAD7 and CHIT1 in the IPF
patients (Fig 6B). To further investigate the interactions between
these moieties, alveolar epithelial cells (alveolar type 1 [AT1] +
alveolar type 2 cells [AT2]) were isolated from controls and IPF
patients, and the levels of mRNA encoding CHIT1 and SMAD7 were
characterized. These evaluations revealed increased levels of
expression of CHIT1, decreased levels of SMAD7 expression, and an
inverse correlation between the expression of CHIT1 and SMAD7 in
cells from IPF patients (Fig 6 C–E). Interestingly, when AT1 and AT2
cells were evaluated separately, CHIT1 and SMAD7 were similarly
regulated (Fig S3). As seen in our murine modeling systems, these
studies demonstrate that, CHIT1 is up-regulated in patients with
IPF where its expression correlates inversely with the expression
of SMAD7.
Decreased SMAD7 expression in the lungs from patients with
SSc-ILD
Previous studies from our laboratory, demonstrated that the levels
of CHIT1 activity in the circulation of patients with SSc-ILD are
increased where they correlate with abnormal lung function (Lee
et al, 2012). To determine if themurine and IPF ﬁndings noted above
are also relevant to SSc-ILD, we also evaluated the expression of
SMAD7 in tissues from these patients and determined if the levels of
CHIT1 activity correlated with disease progression. As can be seen in
Fig 7A and B, the levels of expression of SMAD7 were decreased
in lungs from patients with SSc-ILD when compared with controls.
In addition, the levels of circulating CHIT1 activity were increased in
the patients with progressive SSc-ILD compared with stable SSc-ILD
(Fig 7C), and overall progression-free survival was decreased in
patients with increased levels of CHIT1 activity in a manner that
persisted even after adjustment for the relevant covariates of age,
gender, race, and smoking status (Fig 7D). These ﬁndings demon-
strate that CHIT1 is induced, whereas Samd7 is inhibited in SSc-ILD
and support the concept that the CHIT1/SMAD7 axis plays a critical
role in the development and progression of pulmonary ﬁbrosis in
SSc-ILD.
Discussion
Although mammals do not have chitin or chitin synthase, sub-
stantial levels of chitinases and chitinase-like proteins are noted in
the circulation as well as in local tissues (Lee et al, 2009, 2011; Cho et
al, 2015). CHIT1, a major enzymatically active true chitinase, is
produced, stored, and secreted by macrophages and neutrophils
(van Eijk et al, 2005) and plays important roles in innate immune
homeostasis (Elias et al, 2005). This can be appreciated in the
pivotal roles it plays in host defenses against chitin-containing
analysis on the activation of TGF-β signaling (MAPK/Erk, Akt and, and Smad2) and Smad7 expression using lung lysates from WT and TGF-β and Chit1 Tg mice.
β-actin was used as an internal control. The values in panels A and B represent the mean ± SEM of ﬁve mice each group. Panels D and E are representative Western blots
in a minimum of three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001, t test. Bars in panel C, 100 μm.
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pathogens such as fungi, protozoa, and insects (Boot et al, 2001). As
a sensitive biomarker of macrophage activation, dysregulated ex-
pression of CHIT1 in the circulation or local tissue has been re-
ported in a variety of human diseases, including Gaucher’s disease,
diabetes, sarcoidosis, inﬂammatory bowel disease, atherosclerosis,
Alzheimer’s disease, and prostate cancer (Kanneganti et al, 2012;
Elmonem et al, 2016). Recent studies from our laboratory and others
also demonstrated that CHIT1 is dysregulated in lung diseases
characterized by inﬂammation and remodeling such as bacterial
infection, asthma, chronic obstructive pulmonary disease, and pul-
monary ﬁbrosis (Lee et al, 2012; Cho et al, 2015; James et al, 2016; Hong
et al, 2018; Sharma et al, 2018). However, the speciﬁcmechanisms that
CHIT1 uses to contribute to the pathogenesis of speciﬁc disease have
not been fully understood. This is particularly true for CHIT1 in
pulmonary ﬁbrosis. Although we reported an important role of CHIT1
in the pathogenesis of SSc-ILD, however, the exact mechanism that
CHIT1 uses to regulate pulmonary ﬁbrosis has not been determined
and the relevance to other forms of ILD remains uncertain.
In this study, we demonstrated that CHIT1 synergistically en-
hances TGF-β–stimulated ﬁbroblast proliferation and myoﬁbro-
blast transformation, and CHIT1 is sufﬁcient and necessary for
optimal TGF-β–stimulated ECM deposition in the lungs. We iden-
tiﬁed TGFBRAP1 and FOXO3 as interacting partners of CHIT1 that
regulate TGF-β signaling and effector functions. Our studies further
demonstrated that CHIT1 enhances TGF-β–stimulated activation of
SMAD2/3, AKT, and MAPK/ERK pathways mainly through TGFBRAP1
while inhibiting the expression of SMAD7, a prototype of inhibitory
SMAD of TGF-β signaling, via interaction with FOXO3. In support of
these ﬁndings, we also noted increased expression of CHIT1 in the
lungs or circulation of the patients with IPF or SSc-ILD, and the
levels of CHIT1 were inversely correlated with SMAD7 expression in
the lungs of these patients. When viewed in combination, these
studies demonstrated a signiﬁcant role of CHIT1 in the patho-
genesis of pulmonary ﬁbrosis via regulation of canonical and
noncanonical TGF-β–stimulated signaling and SMAD7 expression.
IPF, a prototypic ﬁbrotic disorder, is a progressive lung disease
characterized by epithelial damage, ﬁbroproliferative matrix de-
position, and parenchymal remodeling (Raghu, 1998; Selman et al,
2001; Krein & Winston, 2002). TGF-β is believed to play an important
role in this dysregulation because it is expressed in an exaggerated
fashion in IPF where, in contrast to controls, a sizable percentage is
biologically active (Khalil et al, 1996, 2001; Xu et al, 2003). The im-
portant role that TGF-β may play in this disorder can be seen in
studies that demonstrate that TGF-β is a critical mediator of pul-
monary ﬁbrosis after bleomycin injury (Nakao et al, 1999;
Yehualaeshet et al, 2000) and that transgenic overexpression in the
lung or high-dose adenoviral TGF-β1 transfer causes progressive
pulmonary ﬁbrosis in vivo (Sime et al, 1997; Kelly et al, 2003; Lee et al,
Figure 3. CHIT1 interacts with TGFBRAP1 and FOXO3.
(A) Co-immunoprecipitation (IP) and immunoblot (IB)
evaluations on the MLE12 epithelial cells transfected
with CHIT1, TGFBRAP1, and FOXO3 expressing constructs.
(B) Double-labeled ﬂuorescent IHC to localize
expression of CHIT1, TGFBRAP1, and FOXO3 in NHLF.
Panels A and B are representative Western blots and
IHC evaluations of three separate experiments,
respectively. Bars in panel B, 50 μm.
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2004) and IPF-like ﬁbroblastic foci in in vitro explants (Xu et al,
2003). It is also interesting to note that TGF-β requires other co-
factors that activate or enhance TGF-β signaling in the develop-
ment of persistent ﬁbrosis in the lung or other organs (Mori et al,
1999; Leask, 2006; Tatler & Jenkins, 2012). In this regard, present
studies support a possibility that CHIT1 could be the one that
enhances the signaling and effector function of TGF-β in the
development of pulmonary ﬁbrosis. In the previous studies, we
demonstrated that overexpression of IL-13 induced prominent
pulmonary ﬁbrosis with increased expression of both TGF-β and
CHIT1 (Lee et al, 2012). We also demonstrated that null mutation of
CHIT1 without direct intervention of TGF-β signiﬁcantly reduced
IL-13–induced pulmonary ﬁbrosis, suggesting a critical role of CHIT1
in TGF-β effector function in tissue ﬁbrosis (Lee et al, 2012). Col-
lectively, these ﬁndings suggest that CHIT1 plays an essential role in
the pathogenesis of pulmonary ﬁbrosis in which CHIT1 and TGF-β
are dysregulated. In this regard, it is reasonable to speculate that
CHIT1 also could play an important role in the pathogenesis of other
organ ﬁbrosis including sarcoidosis and nonalcoholic steatohe-
patitis that showed dysregulated levels of both CHIT1 and TGF-β
(Peverill et al, 2014; Casanova et al, 2015).
Recently, Van Dyken et al (2017) reported that acidic mammalian
chitinase (AMCase) plays a protective role in spontaneously de-
veloped pulmonary ﬁbrosis related to chitin polymer accumulation
in the lung. AMCase and CHIT1 are two true chitinases in mammals
and have different cellular and tissue expression and physiologic
function, although they share similar chitinolytic enzyme activity
with different reaction conditions. It has been shown that AMCase,
but not CHIT1, is prominently expressed in themurine lung, whereas
the expression of Chit1 (both in endogenous and induced ex-
pression) is predominant in human lungs (Boot et al, 2005). Because
the physiologic role of AMCase in the lungs is more likely adapted to
the chitin-rich environment, it is reasonable to speculate that
decreased chitinase activity of AMCase in murine lung results into
chitin accumulation. However, in human lungs, there is no en-
dogenous source of chitin, and CHIT1 enzyme activity was reported
to be increased with ageing (Kurt et al, 2007) and in the lungs of IPF
(Bargagli et al, 2007). These studies suggest that enzymatic de-
ﬁciency of AMCase may not fully explain human lung pathologies
without simultaneous consideration of Chit1, the major true chi-
tinase expressed in human lungs. In addition, recent studies also
support a direct pathogenic role of chitinase-like proteins such as
CHI3L1 that have no chitinase enzyme activity with retained chitin-
binding ability, in tissue remodeling and ﬁbrosis (Zhou et al, 2014,
2015). These studies suggest that enzyme activity of either AMCase
or CHIT1 might not be the sole responsible factor for determining
ﬁnal outcome of tissue response associated with chitinase dys-
regulation. When viewed in combination, present studies suggest
that the relative contribution and potential interaction of AMCase
and CHIT1 in the pathogenesis pulmonary ﬁbrosis need to be
further determined in future studies.
In this study, we demonstrate that CHIT1 interacts with in-
tracellular proteins TGFBRAP1 or FOXO3 and regulates major TGF-β
signaling and SMAD7 expression. As a chaperone for SMAD4,
TGFBRAP1 has been shown to associate with inactive heteromeric
TGF-β and activin receptor complexes, mainly through the type 2
receptor, and is released upon activation of signaling and recruit
SMAD4 to the vicinity of the receptor complex to facilitate its in-
teraction with receptor-regulated SMADs, such as SMAD2 (Wurthner
et al, 2001). However, the speciﬁc role of TGFBRAP1 in the patho-
genesis of ﬁbrosis in the lungs or other organs has not been
studied. This is the ﬁrst study showing TGFBRAP1 interacts with
CHIT1 and mediates synergistic effect of CHIT1 on TGF-β–stimulated
canonical and noncanonical signaling. It is also interesting to note
Figure 4. TGFBRAP1 plays a critical role in CHIT1 augmentation of TGF-β1
signaling and TGFβR expression.
(A)Western blot evaluation on the NHLF cells stimulated by rTGF-β and/or rCHIT1
with (+) and without (−) siRNA silencing of TGFBRAP1. Scrambled siRNA was used as
control for TGFBRAP1 speciﬁc siRNA. (B) Evaluation on the SMAD activities on the
cells transfected SMAD2-luciferase construct after stimulated by rTGF-β (20 ng/
ml) and/or rCHIT1 (100 or 200 ng/ml) with and without siRNA silencing of
TGFBRAP1. Panel A is a representative immunoblot of three separate experiments.
Values in panel B represent the mean ± SEM of triplicated evaluations in a
minimum of two separate experiments. *P < 0.05, **P < 0.01, one-way ANOVA.
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that silencing of TGFBRAP1 itself on normal lung ﬁbroblasts min-
imally alters the TGF-β activation of SMAD2 or MAPK/ERK, but CHIT1
effects on these TGF-β signaling activation were abrogated, sug-
gesting that TGFBRAP1 is a ﬁne tuner of TGF-β signaling and effector
function in the lung. It is also interesting to note that there is
modest decrease in the expression of TGFβR1 expression with
silencing of TGFBRAP1, suggesting that CHIT1 regulates TGF-β
receptor expression via TGFBRAP1, at least in part.
Because silencing of TGFBRAP1 did not alter CHIT1 inhibition of
TGF-β–stimulated SMAD7 expression, we sought other mecha-
nism(s) responsible for CHIT1 regulation of SMAD7 expression. Our
studies demonstrated that FOXO3, a transcriptional factor that has
a binding consensus sequence in the promoter region of SMAD7,
plays a critical role in TGF-β and CHIT1-regulated expression of
SMAD7. TGF-β itself induced the expression and phosphorylation
of both cytoplasmic and nuclear FOXO3. Interestingly, CHIT1 in-
creases the levels of pFOXO3 in the cytoplasmic compartment with
depletion pFOXO3 in nuclear fraction. These studies suggest that
CHIT1 plays a role in nuclear/cytoplasmic shuttling and cyto-
plasmic retention of pFOXO3, which might limit the accessibility of
FOXO3 in the nuclear fraction, resulted into decreased tran-
scriptional activity of FOXO3 for SMAD7 or other FOXO3 target
Figure 5. TGF-β stimulates SMAD7 expression via
FOXO3.
(A) Real-time qRT-PCR evaluations on the NHLF cells
after stimulation with rTGF-β (10 ng/ml) and rCHIT1 (250
ng/ml) with (+) and without (−) siRNA silencing of
FOXO3. (B) HEK293 cells transfected with luciferase-
tagged SMAD7 promoter construct with (ProSMAD7WT;
WT) and without (ProSMAD7,(FOXO3); mutant form)
FOXO3 consensus sequence were stimulated with rTGF-
β and/or rCHIT1, and then luciferase activity was
measured. (C) Western blot evaluations on the pFOXO3
and FOXO3 expression in the lungs of WT (−), TGF-β Tg
(+), CHIT1 Tg (+), and CHIT1/TGF-β Tg mice. Whole-lung
lysates were further separated into cytoplasmic and
nuclear fractions and subjected to the immunoblots
using anti-pFOXO3 and FOXO3 antibodies. Values in
panels A and B represent the mean ± SEM of triplicated
evaluations in a minimum of two separate experiments.
Panel C is a representative immunoblot of three
separate experiments. H3, histone H3, used as internal
control of nuclear protein. **P < 0.01, ***P < 0.001, one-
way ANOVA. ns, not signiﬁcant.
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genes. Because our studies show that FOXO3 is essential for the
expression of SMAD7, these results provide a potential mechanism
to explain the inverse relationship between the levels of CHIT1 and
SMAD7 expression noted in the lungs of IPF patients. In the pre-
vious studies, ﬁbroblasts established from the patients with IPF
showed that pathologic alteration of FOXO3 with reduced ex-
pression contribute to the progression of IPF by protecting ﬁ-
broblasts from apoptotic or autophagic cell death responses (Im
et al, 2015; Nho et al, 2011, 2013). It has been shown that Akt phos-
phorylation of FOXO3 resulted into nuclear cytoplasmic transport,
and subsequent ubiquitination of this phosphorylated form of
FOXO3 after binding with 14-3-3 protein is the major pathway of
lowering FOXO3 levels in the ﬁbroblasts or other cells (Kato et al,
2006; Tzivion et al, 2011; Im et al, 2015). A recent study also reported
a critical role of FOXO3 in ﬁbrogenesis and reduced expression of
FOXO3 was implicated in the pathogenesis of IPF (Al-Tamari et al,
2018). Thus, current data are consistent with these ﬁndings in the
sense that CHIT1 could contribute to the progression of pulmonary
ﬁbrosis via alteration of nuclear FOXO3 levels. However, the
mechanism of CHIT1 regulation of cytosolic retention of pFOXO3 is
not clear yet. Because increased levels of CHIT1 in ﬁbrotic lungs of
bleomycin-challenged mice were noted mainly in the cytoplasmic
and perinuclear area of the cells (Fig S4), it is intriguing to
speculate that physical binding between CHIT1 and pFOXO3 could
be a reason for enhanced cytoplasmic retention of this moiety in
the lung. It is also possible that CHIT1 uses other mechanism of
pFOXO3 regulation such as interaction with 14-3-3 protein that
facilitates the nuclear/cytosolic shuttling of pFOXO3 (Tzivion et al,
2011). These possibilities remain to be determined in the future
studies.
SMAD7, a major inhibitory SMAD of TGF-β signaling, blocks the
function of SMAD2 and SMAD3 by inhibiting their binding to the
activated receptors and exerting its negative effects on TGF-β1/
SMAD signaling (Kavsak et al, 2000; Wang et al, 2016). The speciﬁc
antiﬁbrotic regulatory role of SMAD7 in the pathogenesis of pul-
monary ﬁbrosis has been demonstrated in various conditions.
SMAD7 is the target of microRNAs associated with myoﬁbroblast
differentiation and bleomycin-induced lung ﬁbrosis (Liu et al, 2010;
Wang et al, 2016) and mediates IL-7 suppression of pulmonary ﬁ-
brosis (Huang et al, 2002). In this regard, present studies provide
CHIT1 as a novel negative regulator of SMAD7, which enhances
TGF-β signaling and effector function.
Figure 6. Increased expression levels of CHIT1 in the patients with IPF where they correlate inversely with SMAD7.
(A) Real-time qRT-PCR evaluations on the expression levels of CHIT1 in whole-lung lysates from normal controls and IPF patients. (B) A scatter plot with regression analysis
demonstrating inverse relationship between the levels of CHIT1 and SMAD7 expression in the lungs of IPF patients (Spearman rank test, P = 0.04). (C, D) qRT-PCR
evaluations on CHIT1 and SMAD7 expression in alveolar epithelial cells (alveolar type 1 epithelial cells [AT1] and alveolar type 2 epithelial cells [AT2]) isolated from the lungs
of normal controls and IPF patients. (E) A scatter plot with regression analysis demonstrating inverse relationship between the levels of CHIT1 and SMAD7 in alveolar
epithelial cells isolated from the lungs of IPF patients (P = 0.036, Spearman’s rank test).
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It is interesting to note that dysregulated CHIT1 activity in the
serum was signiﬁcantly associated with progressive SSc-ILD
compared with stable cases and that the levels of CHIT1 activity
were correlated with survival rates of the patients. In the evaluation
of end stage lungs from IPF patients, we also see prominent in-
creases of CHIT1 expression with suppression of SMAD7 expression.
These studies suggest that CHIT1/SMAD7 axis plays an important
role in disease progression or exacerbation rather than initiator of
ﬁbrotic tissue response, and potential use of CHIT1/SMAD7 activity
and expression both in serum and lung or BAL as a biomarker to
predict disease severity and prognosis of patients with IPF and
SSc-ILD.
In conclusion, these studies demonstrated that CHIT1 interacts
with TGFBRAP1 and FOXO3 and enhances TGF-β–stimulated acti-
vation of canonical and noncanonical signaling and the expression
of inhibitory SMAD7. Thus, CHIT1 and its interacting partners of
TGFBRAP1 or FOXO3 could be reasonable therapeutic targets for the
intervention of patients with pulmonary ﬁbrosis in that TGF-β and
CHIT1 are signiﬁcantly dysregulated.
Materials and Methods
Mice
C57 BL/6 mice were purchased from the Jackson Laboratory and
were housed at Brown University animal facilities. TGF-β Tg, Chit1−/−,
and Chit1 Tg mice on C57 BL/6 background were generated and
maintained in our laboratory as previously described (Lee et al,
2004, 2012). Both TGF-β Tg and Chit1 Tg mice are lung-speciﬁc in-
ducible transgenic mice, and transgene expression was induced by
drinking water containing doxycycline (0.5 g/l). The mice with null
mutation or overexpression of Chit1 did not show any apparent
abnormal phenotypes and developmental and signaling issues. All
murine procedures were approved by the Institutional Animal Care
and Use Committees at Brown University.
Cell culture
NHLF cells and human embryonic kidney 293 cells (HEK293) were
obtained from Lonza and American Type Culture Collection (ATCC),
respectively. NHLF cells were cultured in ﬁbroblast growth medium
(Lonza CC-2512B) at 37°C in 5% CO2. HEK293 cells were maintained in
DMEM supplemented with 10% FBS and 100 U/ml penicillin and 100
μg/ml streptomycin at 37°C in 5% CO2 incubator. NHLF cells were
used within 10 passages according to the manufacturer's recom-
mendation. MLE12 murine-transformed lung epithelial cells were
purchased from ATCC and cultured andmaintained using DMEM-F12
medium supplemented with 10% FBS as recommended.
siRNA silencing of TGFBRAP-1 and FOXO3
siRNAs speciﬁc for human TGFBRAP1 (SC-36720; Santa Cruz) and
FOXO3 (SC-37887; Santa Cruz) were used for silencing the levels of
mRNA encoding TGFBRAP1 and FOXO3 as per the manufacturer’s
instructions. NHLF cells were seeded on six-well plates and
transfected the next day with TGFBRAP1, FOXO3, or control siRNAs.
Figure 7. Decreased SMAD7 expression in the lungs
from patients with SSc-ILD.
(A) IHC evaluation on the SMAD7 expression in the lung
sections from normal control and patients with SSc-ILD.
SMAD7 staining of SSc-ILD lungs (right) reveals
decreased number of Samd7-positive cells especially in
the stromal region as compared with normal control
(left) that showed a number of parenchymal cells and
alsomacrophages are strongly stained. (B)Quantitation
of SMAD7-positive (+) cells in the lung sections from
controls and SSc-ILD per high-powered ﬁeld. (C) Serum
CHIT1 activity in the SSc-ILD patients with stable and
progressive lung function. “Progressive” was deﬁned in
the patients with more than 10% of absolute drop of
forced vital capacity (FVC). (D) Survival analysis based
on the levels of chitinase activity (below and above
median value of 53.54 nM/ml/h) in the patients with
SSc-ILD. SSc-ILD subjects (n = 56) with values exceeding
the median value of 53.54 (dotted line) demonstrate
reduced progression-free survival as deﬁned by
absolute loss of %FVC within 2 years of enrollment.
Scale bars, 30 μm, **P < 0.01, ***P < 0.001, Spearman’s
rank test. n, number of individuals subjected to the
evaluation.
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The cells were collected at the indicated time points and were
subjected to real-time (RT)-PCR or Western blot evaluations.
Co-IP and IB analysis
To assess interactions among CHIT1, TGFBRAP-1, and FOXO3, MLE12
murine lung epithelial cells were co-transfected with TGFBRAP1 and
FOXO3 plasmids (pcDNA3.1). Lysates from these cells were sub-
jected to immunoprecipitation using anti-hCHIT1 mouse mono-
clonal antibody (1/500 dilution, AF3559, R&D system). The Catch and
Release V2.0 (Reversible Immunoprecipitation System; EMD Milli-
pore) kit was used for Co-IP according to the manufacturer’s in-
struction. The precipitates were then evaluated by immunoblotting
with antibodies against CHIT1, TGFBRAP1, or FOXO3.
Co-localization with double-label IHC
To localize the expression of CHIT1, TGFBRAP1, and FOXO3, double-
label IHC was undertaken with a modiﬁcation of procedures de-
scribed previously by our laboratory (Lee et al, 2016). NHLF cells (1 ×
106 cells/well) were cultured overnight in four-well chamber slides
(Falcon) at 37°C in 5% CO2 incubator, then washed with PBS. To
unmask antigens, the slides were placed for 20 min at high tem-
perature under high pressure in citrate buffer (10 mM sodium
citrate, 0.05% Tween 20, pH 6). The slides were then blocked with a
nonserum protein-blocking reagent (DakoCytomation Inc) for 1 h at
room temperature and incubated with primary antibodies (anti-
CHIT1 [1/50 dilution, AF-5325; R&D system], anti-TGFBRAP1 [1/50
dilution, SC-13134; Santa Cruz Biotechnology], and anti-FOXO3 [1/50
dilution, 12829S; Cell Signaling]) for 60min at room temperature in a
humid chamber. Substitution of the primary antibody with PBS
served as a negative control. The slides were then washed in PBST
(0.01% Tween 20) and incubated with secondary antibodies con-
jugated with horseradish peroxidase (Cell Signaling). Reaction
products were developed using DAB containing 0.3% hydrogen
peroxide up to 5 min. Cell nuclei were stained with mounting
medium with DAPI (50 μl, H-1200; Vector Laboratories). Fluores-
cence was detected by Immunoﬂuorescence microscopy.
Evaluation of TGF-β signaling
Canonical SMAD activity of TGF-β1 signaling pathway was assessed
using dual reporter assays (SABiosciences). A SMAD-responsive
ﬁreﬂy luciferase construct that constitutively expressed Renilla
luciferase was transfected into NHLF cells. After stimulation with
recombinant CHIT1 and TGF-β1, alone or in combination, SMAD
activation was assessed by measuring the dual luciferase activities.
SMAD2 activation and MAPK/ERK, AKT activation were evaluated by
Western blot as previously described (Lee et al, 2004). The ex-
pression of SMAD7 was evaluated by immunoblot assay using anti-
SMAD7 polyclonal rabbit antibody (Santa Cruz Biotechnology).
Evaluation of FOXO3 and SMAD7 interaction
HEK293 cells were seeded at a density of 1 × 106 cells/well in six-well
dishes and grown to 70% conﬂuence. For each well, 1 μg of pEZX-
PG04-SMAD7 promoter construct (GeneCopoeia, Inc.) or 1 μg of the
FOXO3-binding site point-mutated SMAD7 promoter were trans-
fected into the cells with the Lipofectamine 3000 transfection
reagent. After stimulation with rCHIT1 and rTGF-β1, alone or in
combination, SMAD7 expression was assessed by measuring the
Secrete-Pair Dual Luminescence Assay kit (GeneCopoeia, Inc.) and
was normalized with secreted alkaline phosphatase activity
within each sample.
Evaluation on the levels of cytosolic and nuclear pFOXO3 and
FOXO3
Phosphorylation and cytoplasmic/nuclear shuttling are the major
pathways regulating transcriptional activity of FOXO3 (Nho & Hergert,
2014). Hence, studies are undertaken to see whether CHIT1 is im-
plicated in this process. For this evaluation, cytosolic and nuclear
fraction of the whole-lung lysates were prepared using nuclear
cytoplasmic extraction reagents (Thermo Fisher Scientiﬁc) according
to the procedures provided by the company and subjected to im-
munoblot evaluation using anti-pFoxO3 (Serine253) (Cell Signaling)
and FoxO3 (D19A7) (Cell Signaling).
Proﬁling of IPF and control lung tissues
Fresh human lung tissue was procured from subjects with end-
stage lung disease, undergoing transplant or donor lungs that were
not implanted at the time of transplant. The demographics and
clinical characteristics of the groups can be seen in Table S2. All
protocols were approved by the Partners Institutional Review
Board. For each subject, small pieces (<5 mm) of whole-lung tissue
were treated with RNAlater (QIAGEN) and snap-frozen in liquid
nitrogen before storage at −80°C.
Isolation of alveolar epithelial cell type 1 and type 2
Fresh human lung explants were sliced and washed with cold
sterile PBS. Visible airway structures, vessels, blood clots, and
mucin were removed. Lung specimens were minced mechanically
into small pieces (<1 mm3) and then incubated for 45 min in 37°C in
modiﬁed medium containing DMEM/F12 with added digestion
enzymes: Liberase thermolysin medium (Roche), elastase (EC-134;
Elastin Products Company), and DNase I (Thermo Fisher Scientiﬁc).
Digested tissue was ﬁltered using a metal strainer. 10% FBS were
added to the ﬂow-through to stop the enzymatic reaction. The
pellet was resuspended in DMEM/F12 medium and ﬁltered using a
100-μm strainer. The cells were resuspended in freezing medium
(10% FBS and 10% DMSO in DMEM/F12), aliquoted, and stored in
liquid nitrogen. Thawed single-cell suspension was sorted using
FACS. Sorting gate for AEC type 1 and type 2 were designed as
follows: DAPI−/CD45−/EpCAM+/PDPN+ and DAPI−/CD45−/EpCAM+/
PDPN−, respectively. Isolated cells from 10 subjects diagnosed with
IPF and 10 controls were used. Patient demographics and clinical
information can be found in Table S3.
Cohort of SSc-ILD patients
These studies were performed with HIC approval at the Yale School
of Medicine. Samples from subjects with SSc-ILD according to
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current EULAR/ACR criteria were used for these studies. As shown in
Table S4, subjects with CHIT1 levels exceeding the median level of
52.39 nM/ml/h weremore likely to be older and to have smoked but
were otherwisematched for gender, race, disease subtype, and lung
function.
Measurement of CHIT1 activity
CHIT1 enzyme activity was assessed as described previously in our
laboratory (Lee et al, 2012).
Localization of SMAD7 expression in SSc
IHC was undertaken to localize SMAD7 protein using polyclonal
rabbit anti human SMAD7 obtained from Santa Cruz Biotechnology
as described in our laboratory (Lee et al, 2009). Lung explants from
patients with SSc-ILD and nonﬁbrotic controls were subjected to
the staining and SMAD7 expressing cells were counted in six
randomly chosen high power ﬁelds. The values averaged and the
mean ± SEM calculated for SSc-ILD versus normal lung.
Statistical analysis
Normality of data was assessed using the D’Agostino–Pearson
omnibus normality test. Normally distributed data are expressed as
the means ± SEM and assessed for signiﬁcance by a t test or ANOVA,
as appropriate. Categorical variables were compared using the
Fisher’s exact test. Nonparametric correlation between two vari-
ables was evaluated by Spearman’s rank test.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900350.
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